Harbour Investments Inc. Lowers Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Harbour Investments Inc. lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 20.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,221 shares of the medical device company’s stock after selling 2,674 shares during the quarter. Harbour Investments Inc.’s holdings in DexCom were worth $795,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc purchased a new position in DexCom during the fourth quarter worth approximately $25,000. Private Trust Co. NA boosted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares in the last quarter. Larson Financial Group LLC boosted its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. purchased a new position in DexCom during the fourth quarter worth approximately $49,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $73.38 on Thursday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $28.67 billion, a P/E ratio of 51.31, a P/E/G ratio of 2.30 and a beta of 1.28. The stock’s fifty day moving average is $83.51 and its two-hundred day moving average is $76.93.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DXCM. Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Citigroup lifted their price target on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Canaccord Genuity Group lifted their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.